Want to see CH:KURN full AI Analyst Report?
KURN Stock Chart & Stats
CHF21.42
CHF0.62(3.13%)
At close: 4:00 PM EDT
CHF21.42
CHF0.62(3.13%)
Day’s Range― - ―
52-Week RangeCHF16.46 - CHF32.48
Previous CloseN/A
Volume158.99K
Average Volume (3M)245.76K
Market Cap
CHF832.51M
Enterprise ValueCHF776.03M
Total Cash (Recent Filing)CHF7.85M
Total Debt (Recent Filing)CHF11.01M
Price to Earnings (P/E)115.7
Beta1.22
Next Earnings
Mar 03, 2027EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding39,756,700
10 Day Avg. Volume348,911
30 Day Avg. Volume245,759
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF33.00Price Target Upside54.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.32
Revenue Forecast (FY)CHF204.27M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And Profitability InflectionStrong sales growth combined with a first half-year profit demonstrates meaningful commercial scaling and improving operating leverage. If execution continues, the expanding revenue base can support reinvestment, strengthen market position, and improve earnings durability over the next several quarters.
High Gross Margins And Conservative LeverageVery high gross margins provide substantial economic value per product sold, while minimal leverage limits interest burden and financial stress. This combination gives Kuros greater flexibility to fund commercialization and manufacturing investments without relying heavily on additional debt.
Commercial Reach And Market-share ExpansionBroader distribution, increasing surgeon utilization, and a rapidly expanding treated-patient base indicate improving adoption of MagnetOs. These gains can create a durable commercial platform, support repeat demand, and increase the effectiveness of future sales investments.
Bears Say
Weak Cash Conversion And Working-capital PressureCash generation has lagged accounting earnings, with operating and free cash flow turning negative after positive prior-year figures. Elevated receivables and continued investment can increase funding sensitivity, limiting flexibility if conversion does not improve as the business scales.
Manufacturing Ramp And Transformation Costs May Dilute MarginsBuilding U.S. production and expanding operational infrastructure should support localization over time, but the transition creates near-term cost pressure before benefits are realized. Lower margins during the ramp could delay operating leverage and make earnings more sensitive to execution.
Profitability Remains Thin Despite Recent ImprovementThe move into profitability is encouraging, but a 1.7% net margin leaves limited protection against slower growth, cost increases, or temporary commercialization expenses. Kuros therefore remains dependent on sustained expansion and further margin improvement to establish durable earnings resilience.
Kuros Biosciences News
KURN FAQ
What was Kuros Biosciences Ltd.’s price range in the past 12 months?
Kuros Biosciences Ltd. lowest stock price was CHF16.46 and its highest was CHF32.48 in the past 12 months.
What is Kuros Biosciences Ltd.’s market cap?
Kuros Biosciences Ltd.’s market cap is CHF832.51M.
When is Kuros Biosciences Ltd.’s upcoming earnings report date?
Kuros Biosciences Ltd.’s upcoming earnings report date is Mar 03, 2027 which is in 125 days.
How were Kuros Biosciences Ltd.’s earnings last quarter?
Kuros Biosciences Ltd. released its earnings results on Aug 13, 2026. The company reported CHF0.06 earnings per share for the quarter, beating the consensus estimate of CHF0.06 by <CHF0.001.
Is Kuros Biosciences Ltd. overvalued?
According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued.
Does Kuros Biosciences Ltd. pay dividends?
Kuros Biosciences Ltd. does not currently pay dividends.
What is Kuros Biosciences Ltd.’s EPS estimate?
Kuros Biosciences Ltd.’s EPS estimate is 0.08.
How many shares outstanding does Kuros Biosciences Ltd. have?
Kuros Biosciences Ltd. has 39,756,700 shares outstanding.
What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?
Kuros Biosciences Ltd. reported an EPS of CHF0.06 in its last earnings report, beating expectations of CHF0.06. Following the earnings report the stock price went up 0.609%.
Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?
Currently, no hedge funds are holding shares in CH:KURN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kuros Biosciences Ltd.
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
KURN Company Deck
KURN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong set of operational and financial achievements (robust +45% H1 revenue growth, first sustained half‑year profitability with CHF 12.5M adjusted EBITDA and CHF 4.4M net profit, improving gross margins, strong clinical evidence and a clear midterm revenue/margin target). These positives are tempered by planned near‑term investments and transformation costs, expected dilution from the U.S. manufacturing ramp, lumpiness in international revenue, and working capital accumulation that creates short-term liquidity sensitivity. On balance, the transformational investments are framed as deliberate and the company maintained conservative near-term guidance while presenting a credible path to >20% adjusted EBITDA by 2028, so the overall tone is confident with manageable near-term risks.View all CH:KURN earnings summariesKURN Stock 12 Month Forecast
Average Price Target
CHF33.00
▲(54.06% Upside)
Technical Analysis
Molecular Partners AG
―
Lonza Group Ltd
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Bachem Holding AG
―